Aurinia Pharmaceuticals Inc.

(AUP:CA)

By |

Profile

Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States followed by China.

Contact Information

Website: www.auriniapharma.com
Email: dbourgeault@auriniapharma.com
Main Phone: +1 250 708-4272
Address: 4464 Markham Street
Address 2: Suite 1203
State: BC
City / Town: Victoria
Country: CAN
Postal Code: V8Z 7X8

Issuer Information

Exchange: TSX
CEO: Peter S. Greenleaf
Employees: 62
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

Profile

Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States followed by China.

Contact Information

Website: www.auriniapharma.com
Email: dbourgeault@auriniapharma.com
Main Phone: +1 250 708-4272
Address: 4464 Markham Street
Address 2: Suite 1203
State: BC
City / Town: Victoria
Country: CAN
Postal Code: V8Z 7X8

Issuer Information

Exchange: TSX
CEO: Peter S. Greenleaf
Employees: 62
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

$ 20.81 $ -0.6 (-2.80%)
Last Price 20.81 Change $ -0.6 Change % -2.80 Tick N/A
Bid N/A Bid Size 0.00 Ask N/A Ask Size 0.00
Open 21.31 High 21.31 Low 20.16 Prev Close 21.41
Last Trade Volume 207,262 52 Wk Hi 28.60 52 Wk Low 4.70
Market Cap 2.3 bi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 112,548,931.00 EPS (TTM) -1.75 PE Ratio N/A Exchange TSX
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 20.94 20.94 20.94 20.94
Low Target Price Estimate 12.8 12.8 12.8 12.8
Mean Target Price Estimate 16.27 16.27 16.27 16.27
Standard Deviation 3.2 3.2 3.2 3.2
Date of Most Recent Estimate 05/11/18 05/11/18 05/11/18 05/11/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 5 5 5 5
Moderate Buy 2 2 2 2
Hold 1 1 1 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.41 1.41 1.41 1.41